TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21817909

Group type: COMPARATOR
Intervention: Direct laryngoscopy (DL) alone
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Direct laryngoscopy (DL) with TrachView videoscope
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: TrachView videoscope
Number of subjects: 37
Study: 20218984

Group type: EXPERIMENTAL
Intervention: Certoparin (3000 U of anti-factor Xa once daily)
Number of subjects: 3239

Group type: COMPARATOR
Intervention: Unfractionated Heparin (UFH) (5000 IU t.i.d.)
Number of subjects: 3239

Group type: EXPERIMENTAL
Intervention: Certoparin
Number of subjects: 3239

Group type: COMPARATOR
Intervention: Unfractionated Heparin (UFH)
Number of subjects: 3239
Study: 17485070

Group type: EXPERIMENTAL
Intervention: GaA1As laser, lambda=660nm, power of 30mW, energy dose of 2J/cm(2), applied directly and perpendicularly into the cavity in a single visit.
Number of subjects: 8

Group type: COMPARATOR
Intervention: No laser therapy (control group).
Number of subjects: 8
Study: 15567809

Group type: EXPERIMENTAL
Intervention: GlideScope (GS)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Direct Laryngoscopy (DL)
Number of subjects: 200
Study: 11994808

Group type: EXPERIMENTAL
Intervention: Treadmill training at fast speed (2.0 mph)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Treadmill training at slow speed (0.5 mph)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Treadmill training at variable speeds (0.5, 1.0, 1.5, 2.0 mph)
Number of subjects: 24
Study: 9816457

Group type: COMPARATOR
Intervention: Robot implantation
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Manual implantation
Number of subjects: 14
Study: 7695337

Group type: EXPERIMENTAL
Intervention: 200 mg clavulanic acid with 2,000 mg amoxicillin
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 400 mg clavulanic acid with 2,000 mg amoxicillin
Number of subjects: 17
Study: 2239840

Group type: EXPERIMENTAL
Intervention: 37% H3PO4 for 60 seconds
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: 37% H3PO4 for 15 seconds
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: 15% H3PO4 for 60 seconds
Number of subjects: 354
Study: 7017081

Group type: EXPERIMENTAL
Intervention: VM-26 (60 mg/sq m on Day 1) plus CCNU (130 mg/sq m on Day 2), repeated every 6 weeks
Number of subjects: 116

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: VM-26 plus CCNU
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: CCNU alone
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Procarbazine
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Age under 50 years
Number of subjects: 116
Study: 31904607

Group type: EXPERIMENTAL
Intervention: Dorsal wrist-spanning plate (DWSP) fixation to the second metacarpal (Group 1)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Dorsal wrist-spanning plate (DWSP) fixation to the third metacarpal (Group 2)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Dorsal wrist-spanning plate (DWSP) fixation to the third metacarpal with an intrafragmentary screw (Group 3)
Number of subjects: 28
Study: 31505191

Group type: EXPERIMENTAL
Intervention: Lavender oil inhalation
Number of subjects: 126

Group type: COMPARATOR
Intervention: Control group (no lavender oil)
Number of subjects: 126
Study: 29169500

Group type: EXPERIMENTAL
Intervention: Heparin-bonded endoluminal grafts
Number of subjects: 125

Group type: COMPARATOR
Intervention: Femoropopliteal bypass
Number of subjects: 125
Study: 26456233

Group type: EXPERIMENTAL
Intervention: Twice-weekly resistance training (2× RT)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Once-weekly resistance training (1× RT)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Twice-weekly balance and tone (BAT)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Both resistance training groups (1× RT and 2× RT)
Number of subjects: 54
Study: 25608543

Group type: EXPERIMENTAL
Intervention: School-based peer leader centered smoking prevention program (5 sessions)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Control group (50 minute lecture)
Number of subjects: 174
Study: 21091860

Group type: EXPERIMENTAL
Intervention: Abacavir
Number of subjects: 247
Study: 19438432

Group type: EXPERIMENTAL
Intervention: Test product (n = 30) applied once daily for 6 months
Number of subjects: 60

Group type: COMPARATOR
Intervention: Vehicle (n = 30) applied once daily for 6 months
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Test product (n = 15)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Vehicle (n = 13)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Test product (n = 15) for 6 months
Number of subjects: 60
Study: 17554147

Group type: EXPERIMENTAL
Intervention: hGH treatment (20, 35, or 50 microg/kg per day)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: hGH treatment
Number of subjects: 139

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 139
Study: 16818924

Group type: EXPERIMENTAL
Intervention: Traditional Chinese acupuncture (TCA)
Number of subjects: 1007

Group type: EXPERIMENTAL
Intervention: Sham acupuncture
Number of subjects: 1007

Group type: COMPARATOR
Intervention: Conservative therapy
Number of subjects: 1007

Group type: EXPERIMENTAL
Intervention: Comparison between TCA and sham acupuncture
Number of subjects: 1007
Study: 12657990

Group type: EXPERIMENTAL
Intervention: 10 mL of PGE(1) (20 microg) solution
Number of subjects: 57

Group type: COMPARATOR
Intervention: 10 mL of saline solution
Number of subjects: 57

Group type: COMPARATOR
Intervention: 10 mL of dexamethasone (8 mg) solution
Number of subjects: 57
Study: 10224546

Group type: EXPERIMENTAL
Intervention: Polyurethane condom
Number of subjects: 805

Group type: COMPARATOR
Intervention: Latex condom
Number of subjects: 805
Study: 8807140

Group type: EXPERIMENTAL
Intervention: Genetic techniques for identifying functional mutations in complex human disorders
Number of subjects: 6000

Group type: EXPERIMENTAL
Intervention: Response to different anti-hypertensive agents
Number of subjects: 6000

Group type: EXPERIMENTAL
Intervention: Recurrence risk for hypertension
Number of subjects: 6000

Group type: EXPERIMENTAL
Intervention: Familial history of hypertension
Number of subjects: 6000

Group type: EXPERIMENTAL
Intervention: Genetic factors in hypertension
Number of subjects: 6000
Study: 1860198

Group type: EXPERIMENTAL
Intervention: Aspirin (325 mg/day)
Number of subjects: 1330

Group type: EXPERIMENTAL
Intervention: Warfarin (dose-adjusted to prolong prothrombin time to 1.3-1.8 times control)
Number of subjects: 1330

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1330

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 1330

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 1330
Study: 6192381

Group type: EXPERIMENTAL
Intervention: Argon laser photocoagulation
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Xenon arc photocoagulation
Number of subjects: 167

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 167
Study: 29402572

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) counseling by a trained oncology nurse
Number of subjects: 240

Group type: COMPARATOR
Intervention: Standard generic information by a physician
Number of subjects: 240
Study: 26952969

Group type: EXPERIMENTAL
Intervention: Needle guide
Number of subjects: 25

Group type: COMPARATOR
Intervention: Normal trials (without needle guide)
Number of subjects: 25
Study: 25904220

Group type: EXPERIMENTAL
Intervention: Betahistine 50 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Betahistine 100 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Betahistine 200 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23973139

Group type: EXPERIMENTAL
Intervention: Post-discharge pain management behaviors and pain intensity assessment
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Information on analgesics and non-pharmacological methods for pain relief
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Perceptions of analgesic use
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Walking and exercise times
Number of subjects: 171
Study: 20734206

Group type: EXPERIMENTAL
Intervention: Pancreaticojejunostomy performed by trainee surgeons in Group B (fibrotic pancreas)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Pancreaticojejunostomy performed by experienced surgeons in Group A (normal pancreas)
Number of subjects: 72
Study: 18485121

Group type: EXPERIMENTAL
Intervention: 75 IU lutropin alfa with 150 IU follitropin alfa
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo with 150 IU follitropin alfa
Number of subjects: 39
Study: 15728810

Group type: EXPERIMENTAL
Intervention: 40 microg of rFVIIa per kilogram
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: 80 microg of rFVIIa per kilogram
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: 160 microg of rFVIIa per kilogram
Number of subjects: 399

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: rFVIIa (combined groups)
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: rFVIIa
Number of subjects: 399
Study: 12610799

Group type: EXPERIMENTAL
Intervention: AG4263 (n = 24)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo (n = 7)
Number of subjects: 31
Study: 10475314

Group type: EXPERIMENTAL
Intervention: ropivacaine 0.2%
Number of subjects: 10

Group type: COMPARATOR
Intervention: lidocaine 0.5%
Number of subjects: 10
Study: 8671164

Group type: EXPERIMENTAL
Intervention: Cervical cap with intracervical reservoir
Number of subjects: 198

Group type: COMPARATOR
Intervention: Standard intracervical injection
Number of subjects: 198
Study: 1754839

Group type: EXPERIMENTAL
Intervention: Chlorhexidine (CHX, 1%)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: SnF2-amine fluoride (AmF) combination (F-content 1.20%)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo gel (control group)
Number of subjects: 45
Study: 7048657

Group type: EXPERIMENTAL
Intervention: Prophylactic granulocyte transfusions (median 1.45 x 10(10) granulocytes, range 0.28‐3.45 x 10(10))
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Prophylactic granulocyte transfusions
Number of subjects: 24
Study: 31714191

Group type: EXPERIMENTAL
Intervention: FE2mg (2 mg/kg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: FE4mg (4 mg/kg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 12
Study: 31171029

Group type: EXPERIMENTAL
Intervention: Continuous infusion of piperacillin/tazobactam (TZP) guided by daily therapeutic drug monitoring (TDM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Continuous infusion of total daily dose of TZP without TDM guidance (13.5 g TZP in normal renal function)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Continuous infusion of TZP guided by daily TDM
Number of subjects: 0

Group type: COMPARATOR
Intervention: Continuous infusion of TZP without TDM guidance
Number of subjects: 0
Study: 28536015

Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent (EES)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Biolimus-eluting stent (BES)
Number of subjects: 48
Study: 25886918

Group type: EXPERIMENTAL
Intervention: Computerized dosing
Number of subjects: 78

Group type: COMPARATOR
Intervention: Conventional dosing
Number of subjects: 78
Study: 23597054

Group type: EXPERIMENTAL
Intervention: Baseline assessment including physical, cognitive, psychological and social functioning, lifestyle behaviour, physical environment, wellbeing and care utilisation
Number of subjects: 2942

Group type: EXPERIMENTAL
Intervention: Clinical examination including anthropometry, muscle strength, physical performance and OA exam
Number of subjects: 2942

Group type: EXPERIMENTAL
Intervention: Follow-up assessment performed 12-18 months after baseline
Number of subjects: 2942
Study: 21412996

Group type: EXPERIMENTAL
Intervention: 0.125% levobupivacaine (80 ml)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 80
Study: 19663892

Group type: EXPERIMENTAL
Intervention: Maribavir 400 mg p.o. q12 h
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 17873811

Group type: EXPERIMENTAL
Intervention: Boston brace treatment
Number of subjects: 106

Group type: COMPARATOR
Intervention: Observation alone
Number of subjects: 106
Study: 14526317

Group type: EXPERIMENTAL
Intervention: 3 days of ampicillin
Number of subjects: 48

Group type: COMPARATOR
Intervention: 7 days of ampicillin
Number of subjects: 48
Study: 10601063

Group type: EXPERIMENTAL
Intervention: Endoscopic sphincterotomy
Number of subjects: 81

Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 81
Study: 9190842

Group type: EXPERIMENTAL
Intervention: 25 mg of (S)-gallopamil
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 50 mg of pseudoracemic (RS)-gallopamil
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 100 mg of (R)-gallopamil
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: (S)-gallopamil and (RS)-gallopamil
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 25 mg of (R)-gallopamil
Number of subjects: 6
Study: 1398465

Group type: EXPERIMENTAL
Intervention: GH-releasing hormone (GHRH)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control (normal subjects)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 7
Study: 3893513

Group type: EXPERIMENTAL
Intervention: RS-43179 gel
Number of subjects: 30

Group type: COMPARATOR
Intervention: Fluocinolone acetonide (Synalar gel)
Number of subjects: 30
Study: 31486722

Group type: EXPERIMENTAL
Intervention: Trained hepatologist led palliative care (Model 2)
Number of subjects: 1260

Group type: COMPARATOR
Intervention: Consultative palliative care (Model 1)
Number of subjects: 1260
Study: 27139158

Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 250 mg/d
Number of subjects: 697

Group type: EXPERIMENTAL
Intervention: Pregabalin 450 mg/d
Number of subjects: 697

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 697
Study: 25982801

Group type: EXPERIMENTAL
Intervention: Prostate Genetic Score (PGS-33)
Number of subjects: 2244

Group type: EXPERIMENTAL
Intervention: Prostate Specific Antigen (PSA)
Number of subjects: 2244

Group type: EXPERIMENTAL
Intervention: Family history of prostate cancer
Number of subjects: 2244

Group type: EXPERIMENTAL
Intervention: PGS-33 quartiles
Number of subjects: 2244

Group type: EXPERIMENTAL
Intervention: PSA performance
Number of subjects: 2244
Study: 23453081

Group type: EXPERIMENTAL
Intervention: Bilateral correction of the supraorbital rim
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Unilateral correction of the supraorbital rim
Number of subjects: 48

Group type: COMPARATOR
Intervention: Timing of surgery (before or after the age of 1 year)
Number of subjects: 48
Study: 21838614

Group type: EXPERIMENTAL
Intervention: Radical removal of pathologic mucosa with a power microdebrider (group A)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Partial removal of pathologic mucosa (group B)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Enlargement of the maxillary ostium (group C)
Number of subjects: 98

Group type: COMPARATOR
Intervention: All groups (A, B, C)
Number of subjects: 98
Study: 20923540

Group type: EXPERIMENTAL
Intervention: LighterLife Programme (LL)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Low-carbohydrate/high-protein diet (LCHP)
Number of subjects: 120
Study: 17701366

Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting Coroflex Please stent
Number of subjects: 96
Study: 15353828

Group type: EXPERIMENTAL
Intervention: Glycoprotein IIb/IIIa inhibitor (eptifibatide)
Number of subjects: 2064

Group type: COMPARATOR
Intervention: Control (no glycoprotein IIb/IIIa inhibitor)
Number of subjects: 2064
Study: 11444458

Group type: EXPERIMENTAL
Intervention: Intubating laryngeal mask airway (ILM)
Number of subjects: 65
Study: 10865393

Group type: EXPERIMENTAL
Intervention: Sofscale
Number of subjects: 32

Group type: COMPARATOR
Intervention: Root planing alone
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Sofscale application after root planing
Number of subjects: 32
Study: 8521099

Group type: COMPARATOR
Intervention: Stabilization splint
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 75

Group type: COMPARATOR
Intervention: Natural course (no treatment)
Number of subjects: 75
Study: 2232464

Group type: EXPERIMENTAL
Intervention: Emoxipin (10 mg/kg intravenously for 5 days, then 1 mg/kg intramuscularly for 15 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (patients with myocardial infarction)
Number of subjects: 0
Study: 343725

Group type: EXPERIMENTAL
Intervention: Radioactive index measured using a gamma camera
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 30563846

Group type: EXPERIMENTAL
Intervention: SPEAR (resilience-based intervention)
Number of subjects: 707

Group type: COMPARATOR
Intervention: Usual training (control)
Number of subjects: 707
Study: 28177565

Group type: EXPERIMENTAL
Intervention: Capnography monitoring
Number of subjects: 201

Group type: COMPARATOR
Intervention: Pulse oximetry monitoring (Control)
Number of subjects: 201
Study: 26119403

Group type: EXPERIMENTAL
Intervention: Zero-Balance Ultrafiltration (Z-BUF)
Number of subjects: 199

Group type: COMPARATOR
Intervention: No Zero-Balance Ultrafiltration (no-Z-BUF)
Number of subjects: 199
Study: 23816061

Group type: EXPERIMENTAL
Intervention: Escitalopram (10mg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 21735945

Group type: EXPERIMENTAL
Intervention: New toothbrush
Number of subjects: 93

Group type: COMPARATOR
Intervention: 3-month-old toothbrush
Number of subjects: 93
Study: 19467806

Group type: EXPERIMENTAL
Intervention: Repeated doses of dinoprostone gel 0.5mg (Prepidil) every 6 hours (group I)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Repeated doses of dinoprostone gel 0.5mg (Prepidil) every 12 hours (group II)
Number of subjects: 148
Study: 16443860

Group type: EXPERIMENTAL
Intervention: Nicorandil (12 mg intravenously before reperfusion)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Placebo (intravenously before reperfusion)
Number of subjects: 158
Study: 12801074

Group type: EXPERIMENTAL
Intervention: QI-Therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: QI-Meds
Number of subjects: 0

Group type: COMPARATOR
Intervention: UC (Usual Care)
Number of subjects: 0
Study: 10655907

Group type: EXPERIMENTAL
Intervention: Thoracic paravertebral bupivacaine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Thoracic epidural bupivacaine
Number of subjects: 100
Study: 8701417

Group type: EXPERIMENTAL
Intervention: Indobufen 200 mg
Number of subjects: 15

Group type: COMPARATOR
Intervention: Aspirin 500 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Indobufen 200 mg b.i.d. for 7 days
Number of subjects: 15

Group type: COMPARATOR
Intervention: Aspirin 300 mg/d for 7 days
Number of subjects: 15
Study: 2072190

Group type: EXPERIMENTAL
Intervention: Oral triazolam
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 6863645

Group type: EXPERIMENTAL
Intervention: Oral Tetracycline (TCN)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topical Tetracycline (TCN) preparation
Number of subjects: 0
Study: 2858743

Group type: EXPERIMENTAL
Intervention: Mefloquine (250 mg)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Chloroquine (450 mg)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Mefloquine (750 mg)
Number of subjects: 80

Group type: COMPARATOR
Intervention: MSP (750 mg mefloquine plus 3 tablets of 'Fansidar')
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Mefloquine and MSP (both groups)
Number of subjects: 80
Study: 31141300

Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Aerobic Training (AT)
Number of subjects: 248

Group type: COMPARATOR
Intervention: Control
Number of subjects: 248
Study: 29505075

Group type: EXPERIMENTAL
Intervention: Narrated video (vodcast)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Guided readings
Number of subjects: 42
Study: 26684248

Group type: EXPERIMENTAL
Intervention: Sodium nitrite infusion
Number of subjects: 6

Group type: COMPARATOR
Intervention: Saline (placebo control)
Number of subjects: 6
Study: 24885076

Group type: EXPERIMENTAL
Intervention: MusicGlove
Number of subjects: 12

Group type: COMPARATOR
Intervention: Conventional hand therapy
Number of subjects: 12

Group type: COMPARATOR
Intervention: Isometric hand movement training
Number of subjects: 12
Study: 21909033

Group type: EXPERIMENTAL
Intervention: Lateral pinning
Number of subjects: 1615

Group type: COMPARATOR
Intervention: Cross pinning
Number of subjects: 1615
Study: 20968112

Group type: EXPERIMENTAL
Intervention: Fenofibrate (200 mg once a day)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Metformin (500 mg three times a day)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Diet control (diet recommendation)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 120
Study: 18550975

Group type: EXPERIMENTAL
Intervention: Combined elastic and free weight resistance (CR)
Number of subjects: 44
Study: 16494259

Group type: EXPERIMENTAL
Intervention: Olanzapine (n = 3687)
Number of subjects: 6405

Group type: COMPARATOR
Intervention: Risperidone (n = 2718)
Number of subjects: 6405
Study: 12848632

Group type: EXPERIMENTAL
Intervention: Rabeprazole (20 mg once daily)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Patients with a history of dyspepsia
Number of subjects: 150
Study: 10641896

Group type: EXPERIMENTAL
Intervention: Fortune photoscreener
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: MTI photoscreener
Number of subjects: 105
Study: 8896773

Group type: EXPERIMENTAL
Intervention: d-amphetamine (0.25 mg/kg)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 1829514

Group type: EXPERIMENTAL
Intervention: Oral cephalosporins
Number of subjects: 19

Group type: COMPARATOR
Intervention: Oral penicillin
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Both cephalosporins and penicillins
Number of subjects: 19
Study: 6357976

Group type: EXPERIMENTAL
Intervention: Dolgit Creme (5% ibuprofen) applied 3 or more times daily (4-10 cm strip)
Number of subjects: 464

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 464
Study: 31964449

Group type: EXPERIMENTAL
Intervention: AMPH ER TAB 20 mg swallowed (fasted)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: AMPH ER TAB 20 mg chewed (fed/fasted)
Number of subjects: 32

Group type: COMPARATOR
Intervention: AMPH EROS 2.5 mg/mL (fasted)
Number of subjects: 32